Therapy Areas: Oncology
China's BeiGene Opens Regional Office in Basel, Switzerland
18 May 2022 - - Chinese biotechnology company BeiGene, Ltd. (NASDAQ: BGNE) (HKEX: 06160) (SSE: 688235) has opened a new regional office in Basel, Switzerland, the company said.

BeiGene said it has built a European organization, including commercial and clinical teams, and this new location will serve as a hub for the company's operations in the region.

Founded in 2010, BeiGene now counts a global team of over 8,000 colleagues across five continents.

Currently, BeiGene's European organization includes more than 270 colleagues, and the Basel office is expected to initially include 150 colleagues.

The company conducts clinical trials globally and to date has enrolled patients from more than 45 countries, including 25 countries in Europe.

BeiGene's BTK inhibitor zanubrutinib was approved by the European Medicines Agency in November 2021 for treatment of adults with Waldenström's macroglobulinemia and has subsequently received approvals in Great Britain and Switzerland.

On the occasion of the opening event, BeiGene hosted several government representatives and business leaders from the region discussing the value of biotechnology leaders like BeiGene to the greater Basel area.

In addition to the new Basel office, BeiGene has offices around the world, with key operations in Cambridge, Massachusetts and Beijing, China.

BeiGene is committed to advancing best- and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines for patients across the globe.

The company has a growing R and D and medical affairs team of approximately 2,900 colleagues dedicated to advancing more than 100 clinical trials that have involved more than 16,000 subjects.

Its portfolio is directed predominantly by our internal colleagues supporting clinical trials in more than 45 countries and regions.

Hematology-oncology and solid tumor targeted therapies and immuno-oncology are key focus areas for the company, with both mono- and combination therapies prioritized in our research and development.

BeiGene currently has three approved medicines discovered and developed in our own labs: BTK inhibitor Brukinsa in the United States, China, the EU and UK, Canada, Australia and additional international markets; and the non-FC-gamma receptor binding anti-PD-1 antibody tislelizumab as well as the PARP inhibitor pamiparib in China.

BeiGene also partners with companies.

It commercializes a range of oncology medicines in China licensed from Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), EUSA Pharma and Bio-Thera.

We also plan to address greater areas of unmet need globally through our other collaborations including with Mirati Therapeutics, Seagen, and Zymeworks.

In January 2021, BeiGene and Novartis (NYSE: NVS) announced a collaboration granting Novartis rights to co-develop, manufacture, and commercialize BeiGene's anti-PD1 antibody tislelizumab in North America, Europe, and Japan.

Building upon this collaboration, including a biologics license application under FDA review, BeiGene and Novartis announced an option, collaboration and license agreement in December 2021 for BeiGene's TIGIT inhibitor ociperlimab that is in Phase 3 development.

Novartis and BeiGene also entered into a strategic commercial agreement through which BeiGene will promote five approved Novartis Oncology products across designated regions of China.